An Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2018
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Jun 2018 Planned End Date changed from 1 Dec 2020 to 2 Apr 2018.
- 14 Jun 2018 Planned primary completion date changed from 1 Jul 2020 to 2 Apr 2018.
- 14 Jun 2018 Planned initiation date changed from 1 Jul 2017 to 1 Apr 2018.